Gamma-delta T cells for liver cancer that stopped responding to immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination therapy using special immune cells (gamma-delta T cells) along with targeted drugs and immunotherapy for people with advanced liver cancer that is no longer responding to standard treatment. The goal is to see if this approach can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer (stage B or C) that has continued to grow despite at least 3 months of standard treatments including immunotherapy (anti-PD-1) and targeted drugs.
- Your liver function is preserved (Child-Pugh score A or B).
- You are able to take care of yourself (ECOG performance score 0 or 1).
- If you have hepatitis B, you must be on antiviral treatment; if you have hepatitis C, you must have received treatment with direct-acting antivirals.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (gamma-delta T cells) combined with other drugs for people with liver cancer who have not had treatment before. It may help shrink the tumor or slow its growth.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.